Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Nektar Announces Topline Data from HAP Study for NKTR-181

NKTR-181 shows significantly less abuse potential compared to oxycodone.

Read More »

Doctors, nurses among hundreds charged with defrauding U.S. health programs

More than 400 people – including doctors and nurses – have been charged with defrauding Medicare and other federal healthcare programs of $1.3 billion, with many accused of illegally distributing opioids and other narcotics, the Justice Department said.

Read More »

U.S. state, local government lawsuits over opioids face uphill battle

A growing number of U.S. states, counties and cities are filing lawsuits accusing drug companies of deceptively marketing opioid painkillers to downplay their addictiveness, but some lawyers say the industry’s highly regulated nature could pose a hurdle to their success.

Read More »

U.S. prescription drug spending as high as $610 billion by 2021: report

Spending on prescription medicines in the United States will increase 4-7 percent through 2021, reaching $580 billion to $610 billion, according to a report released by QuintilesIMS Holdings.

Read More »

Mallinckrodt agrees to U.S. drug probe settlement

Mallinckrodt Plc agreed to pay $35 million to resolve U.S. probes into its monitoring and reporting of suspicious orders of controlled substances.

Read More »

U.S. senator launches opioid drugmaker probe

U.S. Democratic Senator Claire McCaskill seeking details from the nation’s top opioid drugmakers on their sales and marketing practices.

Read More »

Nektar’s opioid painkiller succeeds in key study

Nektar Therapeutics said its experimental opioid succeeded in a key late-stage study.

Read More »

Data on Trevena’s opioid painkiller irks investors

Only some doses of Trevena’s experimental opioid painkiller were found as effective as morphine in two late-stage studies, though the drug met its main study goals.

Read More »

FDA rejects Amphastar’s nasal opioid overdose treatment

Amphastar Pharmaceuticals Inc. said the U.S. Food and Drug Administration had rejected its application to market an intranasal version of the emergency opioid-overdose treatment, naloxone.

Read More »

Amygdala Acquires GS-6637 from Gilead

Amygdala Neurosciences has agreed to acquire Gilead’s GS-6637, a highly selective ALDH2 inhibitor with the potential to treat behavior and substance addictions.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom